Valiant Laboratories Limited is an India-based Active Pharmaceutical Ingredient (API) manufacturing company. The Company is engaged in manufacturing and dealing in specialty chemicals and pharma intermediates in India and abroad. The Company is focused on manufacturing paracetamol API/bulk drug, which has various applications like uses in treatment of conditions, such as headache, muscle ache, arthritis, back ache, toothache, cold and fever. Incorporated in 1980, Valiant Laboratories Ltd was originally formed as a Partnership Firm under the name and style of M/s. Bharat Chemicals through Deed of Partnership dated October 17, 1980. The said Partnership Firm thereafter converted into a Public Limited Company with the name "Valiant Laboratories Limited" through certificate of incorporation dated August 16, 2021 issued by the Central Registration Centre, Registrar of Companies.
The Company is an Active Pharmaceutical Ingredient (API) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The Company gradually commenced manufacturing of Paracetamol by late 1982. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide - C8H9NO2), is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Paracetamol is often found combined with other drugs in many over-the-counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products.
The company operates a single location manufacturing facility at Tarapur industrial estate. Its manufacturing facility is located at a distance of approximately 150 kilometers from Nhava Sheva Port (JNPT). The manufacturing facility is located at Tarapur Industrial Area, Boisar in the State of Maharashtra, with an annual installed capacity of 9,000 MTPA. Within the Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra, the Company has an in-house R&D infrastructure which is equipped with analytical laboratory and infrastructure for developmental activities in its existing product line.
Valiant Laboratories manufactures finished dosage forms of paracetamol API including Tablets, Capsules, and Other medications. The company has established itself as a focused player in the pharmaceutical intermediates space, with paracetamol being its primary product offering. The strategic location of its manufacturing facility near major ports provides logistical advantages for both domestic and international operations.
For the full year ended March 2025, the company reported a net loss of Rs 2.20 crore as against a net profit of Rs 0.32 crore during the previous year ended March 2024. Sales declined by 26.74% to Rs 133.38 crore in the year ended March 2025 as against Rs 182.06 crore during the previous year ended March 2024.
For the quarter ended March 2025, Valiant Laboratories reported a net profit of Rs 0.70 crore as against a net loss of Rs 1.24 crore during the previous quarter ended March 2024. Sales rose by 88.92% to Rs 57.79 crore in the quarter ended March 2025 as against Rs 30.59 crore during the previous quarter ended March 2024.
- Q3 FY25: Net profit of Rs 2.35 crore vs net loss of Rs 3.50 crore in Q3 FY24
- Q2 FY25: Net loss of Rs 4.74 crore vs net profit of Rs 0.79 crore in Q2 FY24
The market cap of Valiant Laboratories Ltd (VALIANTLAB) is ₹496.55 Cr as of July 9, 2025. Valiant Laboratories Ltd has given a return of -27.01% in the last 1 year. The company had a market capitalisation of ₹444 Cr as on May 30, 2025.
The 52-week high of Valiant Laboratories Ltd (VALIANTLAB) is ₹157.49 and the 52-week low is ₹75.20. The stock trades on both NSE (symbol: VALIANTLAB) and BSE (code: 543998).
The chairman of the company is Velji Gogri, and the managing director is Santosh S Vora. The Company is promoted by Shantilal Shivji Vora, Director and Dhanvallabh Ventures LLP (DVL). The promoter holding stands at 74.9%. There is no promoter pledging in Valiant Laboratories Ltd.
The company has announced a rights issue scheduled to open on July 28, 2025, and will close on August 8, 2025. The Valiant Laboratories Rights issue record date is July 19, 2025. The company is to offer 1,08,62,500 equity shares at a price of ₹75 per share. The Valiant Laboratories Rights issue size will be ₹81.47 Crores. The entitlement ratio is 1:4, meaning 1 rights share for every 4 fully-paid equity shares held on the record date.
In July 2022, the Company formed its wholly owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), to diversify its business activities. This strategic move indicates the company's intention to expand beyond its core paracetamol manufacturing business into other pharmaceutical segments.
- The P/B ratio of Valiant Laboratories Ltd is 1.90 times as on May 30, 2025, a 41% discount to its peers' median range of 3.23 times.
- Since TTM earnings of Valiant Laboratories Ltd are negative, P/E ratio is not available.
- The company has a reasonable debt-to-equity ratio of 45%, which signals a healthy balance sheet.
- The company faces some operational challenges including a low interest coverage ratio and high debtors of 197 days.
- Working capital days have increased from 127 days to 203 days.
Valiant Laboratories operates in the competitive pharmaceutical intermediates sector, with a focused approach on paracetamol API manufacturing. Despite recent financial challenges, the company's strategic location, established manufacturing capabilities, and upcoming rights issue indicate management's commitment to strengthening operations and pursuing growth opportunities.
